Idiopathic Pulmonary Fibrosis

Latest News in Idiopathic Pulmonary Fibrosis

May 30, 2025

Nephronectin (NPNT) is a Crucial Determinant of Idiopathic Pulmonary Fibrosis: Modulating Cellular Senescence via the ITGA3/YAP1 Signaling Axis – Wiley

May 20, 2025

Studies Suggest Peptide May Benefit Idiopathic Pulmonary Fibrosis Patients – respiratory-therapy.com

May 19, 2025

Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective – Respiratory Research

May 18, 2025

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis – NEJM

May 17, 2025

Discovery of potent anti-idiopathic pulmonary fibrosis (IPF) agents based on an o-aminopyridinyl alkynyl scaffold – ScienceDirect.com

34 Active Idiopathic Pulmonary Fibrosis Clinical Trials

As of August 23, 2025

Source: clinicaltrials.gov

LOCATE

CLINICAL TRIALS

BROWSE

FDA-approved DRUGS

WHAT IS

CONGRESS DOING?